Guselkumab for previously treated moderately to severely active Crohn's disease ID6238Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 28 August 2025
Guselkumab for treating moderately to severely active ulcerative colitis [ID6237]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 28 August 2025
Apraglutide for treating short bowel syndrome [ID6533]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC